Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2116 of 5804
-
Desperate patients get early access to experimental brain drug
Disease control NO_LONGER_AVAILABLEThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Last-Resort drug access for leukemia patients
Disease control NO_LONGER_AVAILABLEThis expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.
Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Desperate patients get access to experimental Lab-Made vessel
Disease control TEMPORARILY_NOT_AVAILABLEIndividual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study.
Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:08 UTC
-
Last-Resort cancer drug made available to patients before approval
Disease control AVAILABLEKEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qua…
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Second chance: yescarta offered to lymphoma patients despite manufacturing hiccups
Disease control AVAILABLEThe goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope: expanded access to cemiplimab for cancer patients
Disease control APPROVED_FOR_MARKETINGProvide expanded access of cemiplimab in patients with solid tumors
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Last-Resort drug made available for lymphoma patients
Disease control AVAILABLEProvide compassionate use of odronextamab
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug hope for stubborn hives patients
Disease control AVAILABLEThe purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide access to remibrutinib for adult patients with chronic spontaneous urticaria (CSU)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Second chance: nonconforming CAR-T therapy offered to lymphoma patients
Disease control AVAILABLEThis is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control AVAILABLEThe purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kidney disease patients: managed access to EXV811, atrasentan
Disease control AVAILABLEThe purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for leukemia patients allergic to key chemo drug
Disease control NO_LONGER_AVAILABLEThe purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
Sponsor: Phoenix Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Last-Resort cancer drug made available to patients with no alternatives
Disease control NO_LONGER_AVAILABLEThe expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This expanded access program provides adults with refractory metastatic colorectal cancer (mCRC) and who cannot neither adequately be treated by current standard of care …
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early access program offers investigational meningioma treatment
Disease control AVAILABLEThis Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´…
Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Lifeline for hunter syndrome patients: continued access to Brain-Targeting therapy
Disease control AVAILABLEAs the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Second chance: experimental access to CAR T-Cell therapy for patients whose treatment batches Don't meet commercial standards
Disease control AVAILABLEThe goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Early access to experimental SMA drug apitegromab offered before approval
Disease control NO_LONGER_AVAILABLEThe purpose of this expanded access program (EAP) is to provide access to apitegromab for eligible patients with spinal muscular atrophy (SMA) prior to approval by the local regulatory agency . A medical doctor must decide whether the potential benefit outweighs the risk of recei…
Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental device aims to tame disease without medication
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental device aims to transform disease control
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC